Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 24, 2026
YINN's +18% Rebound: Analyzing the Direxion Daily FTSE China Bull 3X Shares Recovery

YINN's +18% Rebound: Analyzing the Direxion Daily FTSE China Bull 3X Shares Recovery

Key Takeaways

  • YINN surged approximately 18% over the past 30 days, recovering sharply from multi-month lows reached in late June 2026.
  • The ETF remains down roughly 18% over the last quarter, reflecting a volatile V-shaped trajectory: a prolonged selloff followed by a powerful policy-driven rebound.
  • Coordinated interventions by Chinese state-owned capital platforms, large-scale share buybacks, and insurer equity pledges served as the primary catalysts for the recent rally.
  • Foreign institutional sentiment turned markedly more constructive, with Citigroup upgrading Chinese equities to overweight and the IMF raising China's 2026 GDP growth forecast to 4.6%.
  • As a 3x daily leveraged product, YINN amplified both the preceding drawdown and the subsequent recovery, underscoring the elevated volatility inherent in leveraged ETF strategies.

Understanding YINN's Structure and Exposure

Direxion Daily FTSE China Bull 3X Shares (YINN) is a leveraged ETF that seeks to deliver 300% of the daily performance of the FTSE China 50 Index, before fees and expenses. The underlying index comprises the 50 largest and most liquid Chinese companies listed on the Hong Kong Stock Exchange, spanning financials, consumer discretionary, communication services, and technology. YINN achieves its leveraged exposure primarily through swap agreements and a substantial position in the FXI (iShares China Large-Cap ETF), which typically accounts for approximately 60% of net assets. The fund carries an expense ratio of 1.34% and had net assets of roughly $500 million as of mid-2026. Its non-diversified, swap-intensive structure means performance is highly sensitive to daily index moves multiplied by the 3x leverage factor, making it best suited for short-term tactical trading rather than buy-and-hold strategies. I also checked comparable leveraged products using Tickeron’s AI Screener to see how YINN stacks up in terms of volatility metrics.

YINN's Price Moves Over the Past Month and Quarter

Over the past 30 days, YINN climbed approximately 18%, rebounding from a closing low of $23.20 on June 24 to $27.41 by July 23. The rally was not linear; the ETF experienced elevated daily swings characteristic of leveraged products, with several single-day moves exceeding 5% in either direction. Over the broader quarterly window, YINN declined roughly 18%, having traded near $33.38 in late April before a multi-week selloff driven by global risk-off sentiment and external contagion dragged it to its late-June trough. The resulting V-shaped pattern highlights the ETF's acute sensitivity to shifts in Chinese equity sentiment, with 3x daily leverage compressing both the drawdown and the recovery into amplified moves.

Key Factors Behind the Recent Rally

The sharp rebound in YINN was fueled by a confluence of policy interventions and improving investor sentiment toward Chinese equities. In mid-July, China's Securities Regulatory Commission (CSRC) convened a series of investor and industry symposiums, signaling a commitment to market stability and countercyclical regulation. Two state-owned capital platforms, China Reform Holdings and China Chengtong Holdings, announced large-scale stock purchases totaling approximately 600 billion yuan, deploying both self-owned funds and the central bank's share buyback relending facility. Nearly 300 listed companies completed share repurchases exceeding 15 billion yuan in July alone, while major insurers including Ping An, China Life, and CPIC pledged to increase equity allocations toward technology, advanced manufacturing, and other strategic sectors.

External catalysts reinforced the recovery. The IMF upgraded China's 2026 growth forecast to 4.6%, citing robust high-tech manufacturing output and export resilience. Citigroup raised its rating on Chinese equities to overweight, while UBS and Standard Chartered maintained constructive stances, citing attractive valuations and accelerating AI-driven earnings growth. The technology-heavy STAR 50 Index surged over 10% in a single session on July 21, and Hong Kong-listed Chinese large caps tracked by the FTSE China 50 Index posted strong gains. Since YINN's portfolio is effectively a 3x levered bet on those same large-cap Chinese names, the rally translated into outsized gains for the ETF. I ran a quick comparison of sector exposures through Tickeron’s AI Screener to confirm the alignment with the underlying index moves.

Understanding the Quarterly Drawdown

The broader quarterly decline in YINN reflects the substantial drawdown that preceded the late-June policy pivot. From late April through mid-June, Chinese equities faced multiple headwinds. Global risk aversion spiked amid escalating US-Iran geopolitical tensions, rising US Treasury yields, and a recalibration of AI-related valuations across global markets. Contagion from sharp selloffs in US and South Korean technology shares rippled into Hong Kong-listed Chinese stocks. Within China, pre-existing concerns about deflationary pressures, property sector weakness, and high trading congestion in tech names contributed to a significant unwind. The FTSE China 50 Index fell over 5% during the second quarter, and with 3x daily leverage applied, YINN's quarterly decline was amplified to approximately 18% despite the late-period recovery. The quarter thus illustrates the dual-edged nature of leveraged ETF exposure: sustained downtrends compound losses rapidly, while sentiment reversals can generate similarly powerful snapbacks.

YINN ETF Outlook: What Investors Should Watch Next

The trajectory of YINN in the months ahead will depend heavily on whether the policy-driven stabilization in Chinese equities can transition into a more durable, fundamentals-supported recovery. Key factors to monitor include the follow-through on state-owned capital platform purchase commitments, the pace of additional stimulus measures targeting domestic consumption and the property sector, and the trajectory of corporate earnings as mid-year reporting season progresses. On the macroeconomic front, inflation data, PMI readings, and credit growth figures will provide signals on whether China's economic recovery is gaining traction. Externally, US Federal Reserve policy expectations, US-China trade relations, and global risk appetite will influence capital flows into Hong Kong-listed Chinese shares. Given YINN's 3x daily leverage structure, investors should also closely track daily index volatility, as decay effects and compounding can meaningfully impact returns over holding periods longer than a single trading session. The ETF remains a high-octane instrument suited primarily for those with a short-term tactical view on Chinese large-cap equities and a high tolerance for amplified volatility.

Using AI Tools in My Research Process

When evaluating volatile leveraged ETFs like YINN, I frequently rely on Tickeron’s AI Screener to scan thousands of securities for technical indicators, volatility measures, price patterns, and AI-generated signals. It allows me to quickly surface candidates that align with specific performance or risk profiles, streamlining what would otherwise be a time-consuming manual process. This approach has become a regular part of how I cross-check sector exposures and compare emerging-market opportunities before making tactical decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: YINN

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


YINN's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for YINN moved out of overbought territory on August 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YINN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

YINN broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 08, 2026. You may want to consider a long position or call options on YINN as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for YINN just turned positive on July 07, 2026. Looking at past instances where YINN's MACD turned positive, the stock continued to rise in of 61 cases over the following month. The odds of a continued upward trend are .

YINN moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for YINN crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where YINN advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where YINN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the FTSE China 50 Index. The fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, securities of the index, and exchange-traded funds ("ETFs") that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index consists of the 50 largest and most liquid public Chinese companies currently trading on the Hong Kong Stock Exchange. The fund is non-diversified.
View a ticker or compare two or three
YINN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.